VK0214
Small molecule
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
X-ALD NCT04973657 · X-linked Adrenoleukodystrophy Registry: NCT04973657 | 1 | Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs) (28 days) 2024-10-09 | VK0214 in AMN: treatment-emergent adverse events mild to moderate; one severe event (wrist fracture, placebo); GI events 33% placebo vs 11% VK0214. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.